Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VYNE Therapeutics Inc.    VYNE

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

10/07/2020 | 04:14pm EST

Item 7.01. Regulation FD Disclosure.

On October 7, 2020, VYNE Therapeutics Inc. (the "Company") issued a press release entitled "VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts." A copy of the press release is attached as Exhibit 99.1 to this report.

In addition, on October 5, 2020, Patrick LePore, a member of the Company's Board of Directors, entered into a stock trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Company's insider trading policy to purchase shares of the Company's common stock. Under the plan, Mr. LePore intends to purchase 200,000 shares of the Company's common stock at prevailing market prices through his broker over the next twelve months, subject to the terms of the plan. Transactions under Mr. LePore's 10b5-1 plan will be reported to the Securities and Exchange Commission in accordance with applicable securities laws, rules and regulations.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


The following exhibit is furnished herewith.



         Exhibit No.   Description
           99.1          Press Release, dated October 7, 2020.

         104           Cover Page Interactive Date File (embedded within the Inline
                       XBRL document).

© Edgar Online, source Glimpses

All news about VYNE THERAPEUTICS INC.
11/25VYNE THERAPEUTICS : to Present at the 32nd Annual Piper Sandler Healthcare Confe..
AQ
11/25VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conf..
GL
11/05VYNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
11/05VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K..
AQ
11/05VYNE THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Provides Bu..
AQ
11/05VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides B..
GL
10/28VYNE THERAPEUTICS : to Report Third Quarter 2020 Financial Results on November 5..
AQ
10/28VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November ..
GL
10/08VYNE THERAPEUTICS : Announces Covered Status for ZILXI with Express Scripts
AQ
10/07VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
More news
Financials (USD)
Sales 2020 21,9 M - -
Net income 2020 -206 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,86x
Yield 2020 -
Capitalization 277 M 277 M -
Capi. / Sales 2020 12,6x
Capi. / Sales 2021 4,33x
Nbr of Employees 40
Free-Float -
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 7,07 $
Last Close Price 1,65 $
Spread / Highest target 809%
Spread / Average Target 329%
Spread / Lowest Target 81,8%
EPS Revisions